Renishaw
CompanyUnited Kingdom
Renishaw develops one asset, in phase 1 (Cerebral Dopamine Neurotrophic Factor in brain diseases). Mostly protein or enzyme acting on proteostasis, inflammation and CDNF; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 0
- Signals
Pipeline
1Cerebral Dopamine Neurotrophic Factor
Neurotrophic factor alleviating endoplasmic reticulum stress and promoting dopamine neuron survival.
Phase 1, Protein or enzyme, Proteostasis, Inflammation, brain diseases, movement disorders, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Similar companies6